论文部分内容阅读
目的：评价卵巢癌Ｐ糖蛋白、Ｐ１８５表达的临床意义及相互关系。方法：免疫组织化学ＡＢＣ法检测４９份卵巢癌标本Ｐ－糖蛋白、Ｐ１８５的表达。结果：１．卵巢癌Ｐ－糖蛋白、Ｐ１８５表达的阳性率分别为４２．９％和７５．５％，表达阳性者的近期化疗有效率分别为１４．３％和２４．３％，明显低于表达阴性者的近期化疗有效率５３．６％和７５．０％（Ｐ＜０．００５）。２．Ｐ１８５的表达与卵巢癌分化程度和临床分期密切相关（Ｐ＜０．０１、Ｐ＜０．００５），而Ｐ－糖蛋白的表达与卵巢癌分化程度和临床分期无明显相关性（Ｐ＞０．０１、Ｐ＞０．２５）。３．Ｐ－糖蛋白、Ｐ１８５的表达存在相关性（Ｐ＜０．０５）。结论：卵巢癌Ｐ－糖蛋白、Ｐ１８５的过表达明显影响化疗近期疗效，可能是预后不良的肿瘤标志物。Ｐ－糖蛋白、Ｐ１８５表达的相关性值得进一步研究。
Objective: To evaluate the clinical significance and relationship of P glycoprotein and P185 expression in ovarian cancer. Methods: Immunohistochemical ABC method was used to detect the expression of P-glycoprotein and P185 in 49 ovarian cancer specimens. Results: 1. The positive rates of P-glycoprotein and P185 expression in ovarian cancer were 42.9% and 75.5%, respectively. The positive rate of recent chemotherapy was 14.3% and 24.3%, respectively, which were significantly lower than those with negative expression. The effective rate of recent chemotherapy was 53.6% and 75.0% (P<0.005). 2. The expression of P185 was closely related to the differentiation degree and clinical stage of ovarian cancer (P<0.01, P<0.005), but the expression of P-glycoprotein had no correlation with the differentiation degree and clinical stage of ovarian cancer (P>0). .01, P>0.25). 3. There was a correlation between P-glycoprotein and P185 expression (P<0.05). Conclusion: The overexpression of P-glycoprotein and P185 in ovarian cancer significantly affects the short-term efficacy of chemotherapy and may be a poor prognosis tumor marker. The correlation of P-glycoprotein and P185 expression deserves further study.